Investigation of Keros Therapeutics' Recent Clinical Trials
The investigation into Keros Therapeutics, Inc. (NASDAQ: KROS) by law firm Kirby McInerney LLP is raising significant attention. With the firm examining potential claims against Keros, the situation has become quite pressing for investors and concerned parties alike. The firm questions whether Keros has violated federal securities laws or engaged in unauthorized business practices.
Recent Press Releases and Key Events
On December 12, 2024, Keros made headlines by announcing a voluntary halt in its dosing activities within certain arms of the TROPOS trial. This clinical trial, which investigates the efficacy of cibotercept (KER-012) to treat pulmonary arterial hypertension (PAH), included treatment levels of 3.0 mg/kg and 4.5 mg/kg. The company's decision came after a safety review revealed unforeseen adverse events involving pericardial effusion.
Impact on Stock Price
The announcement led to a remarkable decline in the price of Keros shares. From a peak of $68.65 on December 11, 2024, the shares plummeted by approximately 73.15% to close at $18.43 the very next day. Such volatility raises concerns among shareholders regarding the company's communication and operational integrity.
Further Developments in the TROPOS Trial
The situation intensified again on January 15, 2025, when Keros released additional information about halting all dosing in the TROPOS trial. This included the 1.5 mg/kg and placebo treatment arms. The rationale for this decision was tied to ongoing safety reviews brought about by new reports of pericardial effusion adverse events. Keros stressed its commitment to transparency by informing investigators and regulatory authorities, including the FDA, about these developments.
Investor Reaction and Stock Fluctuations
Following this second announcement, Keros' stock experienced another notable drop. From a closing price of $12.48 on January 14, 2025, it decreased to $10.42 the day after the news broke, reflecting a worrying trend for investors within the medical research community. These fluctuations highlight the potential implications for shareholders, particularly those who acquired Keros securities recently.
Contact for More Information
For anyone who purchased Keros securities or possesses relevant information regarding the ongoing investigation, Kirby McInerney LLP encourages direct outreach. You can contact Thomas W. Elrod of the firm to discuss your rights related to these matters.
About Kirby McInerney LLP
Based in New York, Kirby McInerney LLP is dedicated to serving as a plaintiffs’ law firm, focusing on securities, antitrust, whistleblower, and consumer litigation. The firm is well-known for representing shareholders in various securities-related litigations, achieving recoveries that have totaled in the billions. Their goal is to ensure that investors receive justice and accountability in the companies they invest in.
Frequently Asked Questions
What is the investigation into Keros Therapeutics about?
The investigation focuses on potential violations of federal securities laws and possible unlawful business practices by Keros Therapeutics.
How did the stock price of Keros fluctuate recently?
After the announcement regarding halting dosing in the TROPOS trial, Keros' shares dropped significantly, reflecting a 73.15% decline within 24 hours.
Who can I contact for more information about the investigation?
If you have concerns or information, you can reach out to Thomas W. Elrod at Kirby McInerney LLP.
What are the main concerns regarding Keros Therapeutics?
Investors are concerned about the company's transparency and communication regarding adverse events in their clinical trials.
What kind of law firm is Kirby McInerney LLP?
Kirby McInerney LLP specializes in securities, antitrust, whistleblower, and consumer litigation, representing investors in various legal matters.
